Pharmaceutical

AdAlta and SYNthesis to form AdCella for advanced cancer treatments

AdAlta has signed an MOU with SYNthesis to explore the creation of a jointly owned special purpose entity, AdCella.

Apr 9, 2024 - 00:00
AdAlta and SYNthesis to form AdCella for advanced cancer treatments
AdAlta has signed an MOU with SYNthesis to explore the creation of a jointly owned special purpose entity, AdCella.
Read the original article

Tags:

Previous Article

Sensorion raises $16m for gene therapies to treat deafness

Next Article

Medicxi and Starpharma to develop dendrimer-based cancer treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MYK-224 by Bristol-Myers Squibb for Diastolic Heart Fai...

Feb 16, 2024

Ascidian launches first-ever clinical study of RNA exon editor for vision loss

Ascidian launches first-ever clinical study of RNA exon...

Jan 29, 2024

STAT+: Generic group sues Minnesota over a drug pricing transparency law it calls an ‘unconstitutional overreach’

STAT+: Generic group sues Minnesota over a drug pricing...

Jul 6, 2023